ID

31640

Description

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00992186

Link

https://clinicaltrials.gov/show/NCT00992186

Keywords

Versions (1)
  1. 9/15/18 9/15/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 15, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT00992186

English

Eligibility Prostate Cancer NCT00992186

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histological documentation of adenocarcinoma of the prostate
Description

Adenocarcinoma of prostate

Data type

boolean

Alias
UMLS CUI [1]
C0007112
received at least 1 but no more than 2 prior docetaxel-based chemotherapy regimens and had disease progression following the last therapy
Description

Docetaxel Prior Chemotherapy Quantity | Disease Progression Post Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C1514457
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C0087111
serum prostate specific antigen (psa) greater than or equal to 5.0 nanogram/milliliter (ng/ml) within 4 weeks prior to the first dose of study agent
Description

Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201544
orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram/deciliter by means of pharmacological/chemical castration within 4 weeks prior to the first dose of study agent
Description

Orchiectomy | Testosterone measurement | Medical Castration | Chemical male castration

Data type

boolean

Alias
UMLS CUI [1]
C0029189
UMLS CUI [2]
C0523912
UMLS CUI [3]
C1513054
UMLS CUI [4]
C0455189
at least 6 weeks from prior docetaxel chemotherapy regimen to first dose of study agent
Description

Docetaxel Prior Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C1514457
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
experience a hormonal treatment withdrawal response (including a lowering of psa that was previously rising or symptomatic improvement)
Description

Hormone Therapy Withdrawal Response | Prostatic specific antigen decreased | Raised prostate specific antigen Previous | Improvement Symptomatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C2349954
UMLS CUI [1,3]
C1704632
UMLS CUI [2]
C0178414
UMLS CUI [3,1]
C0178415
UMLS CUI [3,2]
C0205156
UMLS CUI [4,1]
C2986411
UMLS CUI [4,2]
C0231220
known or symptomatic central nervous system metastases
Description

CNS metastases | CNS metastases Symptomatic

Data type

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
residual toxicities resulting from previous therapy that are grade 2 or more (except for alopecia)
Description

Toxicity Due to Prior Therapy CTCAE Grades | Exception Relationship Alopecia

Data type

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514463
UMLS CUI [1,4]
C1516728
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0439849
UMLS CUI [2,3]
C0002170
known allergies, hypersensitivity, or intolerance to carlumab or its excipients or clinically significant reactions to chimeric or human proteins
Description

Hypersensitivity Carlumab | Intolerance to Carlumab | Hypersensitivity Carlumab Excipient | Intolerance to Carlumab Excipient | Reaction Clinical Significance Fusion protein | Reaction Clinical Significance Proteins Human

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C2346793
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2346793
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C2346793
UMLS CUI [3,3]
C0015237
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C2346793
UMLS CUI [4,3]
C0015237
UMLS CUI [5,1]
C0443286
UMLS CUI [5,2]
C2826293
UMLS CUI [5,3]
C0162768
UMLS CUI [6,1]
C0443286
UMLS CUI [6,2]
C2826293
UMLS CUI [6,3]
C0033684
UMLS CUI [6,4]
C0086418
vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study agent
Description

Vaccines, Attenuated

Data type

boolean

Alias
UMLS CUI [1]
C0042211
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT00992186

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
histological documentation of adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Docetaxel Prior Chemotherapy Quantity | Disease Progression Post Therapeutic procedure
Item
received at least 1 but no more than 2 prior docetaxel-based chemotherapy regimens and had disease progression following the last therapy
boolean
C0246415 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Prostate specific antigen measurement
Item
serum prostate specific antigen (psa) greater than or equal to 5.0 nanogram/milliliter (ng/ml) within 4 weeks prior to the first dose of study agent
boolean
C0201544 (UMLS CUI [1])
Orchiectomy | Testosterone measurement | Medical Castration | Chemical male castration
Item
orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram/deciliter by means of pharmacological/chemical castration within 4 weeks prior to the first dose of study agent
boolean
C0029189 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
C1513054 (UMLS CUI [3])
C0455189 (UMLS CUI [4])
Docetaxel Prior Chemotherapy
Item
at least 6 weeks from prior docetaxel chemotherapy regimen to first dose of study agent
boolean
C0246415 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy Withdrawal Response | Prostatic specific antigen decreased | Raised prostate specific antigen Previous | Improvement Symptomatic
Item
experience a hormonal treatment withdrawal response (including a lowering of psa that was previously rising or symptomatic improvement)
boolean
C0279025 (UMLS CUI [1,1])
C2349954 (UMLS CUI [1,2])
C1704632 (UMLS CUI [1,3])
C0178414 (UMLS CUI [2])
C0178415 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C2986411 (UMLS CUI [4,1])
C0231220 (UMLS CUI [4,2])
CNS metastases | CNS metastases Symptomatic
Item
known or symptomatic central nervous system metastases
boolean
C0686377 (UMLS CUI [1])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Toxicity Due to Prior Therapy CTCAE Grades | Exception Relationship Alopecia
Item
residual toxicities resulting from previous therapy that are grade 2 or more (except for alopecia)
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C1516728 (UMLS CUI [1,4])
C1705847 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C0002170 (UMLS CUI [2,3])
Hypersensitivity Carlumab | Intolerance to Carlumab | Hypersensitivity Carlumab Excipient | Intolerance to Carlumab Excipient | Reaction Clinical Significance Fusion protein | Reaction Clinical Significance Proteins Human
Item
known allergies, hypersensitivity, or intolerance to carlumab or its excipients or clinically significant reactions to chimeric or human proteins
boolean
C0020517 (UMLS CUI [1,1])
C2346793 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C2346793 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C2346793 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C2346793 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0443286 (UMLS CUI [5,1])
C2826293 (UMLS CUI [5,2])
C0162768 (UMLS CUI [5,3])
C0443286 (UMLS CUI [6,1])
C2826293 (UMLS CUI [6,2])
C0033684 (UMLS CUI [6,3])
C0086418 (UMLS CUI [6,4])
Vaccines, Attenuated
Item
vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study agent
boolean
C0042211 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial